<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04743102</url>
  </required_header>
  <id_info>
    <org_study_id>BIOPSY-01</org_study_id>
    <nct_id>NCT04743102</nct_id>
  </id_info>
  <brief_title>Multi-points and Full-thickness Biopsy in the Diagnosis of cCR After Neoadjuvant Therapy for Rectal Cancer</brief_title>
  <acronym>BIOPSY</acronym>
  <official_title>Study on the Value of Multi-points and Full-thickness Biopsy in the Diagnosis of Clinical Complete remiSsion After Neoadjuvant Therapy for Rectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Chao Yang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Chao Yang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background There is currently no reliable means to restage rectal cancers after neoadjuvant&#xD;
      chemoradiation. There are still no reliable methods to identify patients with pCR before&#xD;
      radical surgery. As a result, clinical complete response (cCR), defined as no clinical&#xD;
      detectable tumor by physical examination, endoscopic evaluation, and imaging, is designed as&#xD;
      a surrogate endpoint for pCR. However, the concordance between cCR and pCR varies from 22% to&#xD;
      96% in different reports, which questions the clinical value of such strategies. Therefore,&#xD;
      based on rectal diginal examination, serum CEA, MRI, endoscopy examination, we suggested to&#xD;
      add multi-points and full-thickness biopsy technique to further improve the accuracy of cCR.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2028</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Complete Response rate</measure>
    <time_frame>8-12 weeks after preoperative chemoradiotherapy for locally advanced rectal cancer</time_frame>
    <description>Clinical complete response rate between two groups after examinations following preoperative chemoradiotherapy for rectal cancer</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathological complete remission</measure>
    <time_frame>2 weeks after patients received radical operation</time_frame>
    <description>No tumor cell found in surgical specimens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>5 years after operation or &quot;watch and wait&quot; approach</time_frame>
    <description>no tumor regrowth or recurrence or metastasis found</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years after operation or &quot;watch and wait&quot; approach</time_frame>
    <description>survive during following</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Rectal Cancer</condition>
  <condition>Neoadjuvant Therapy</condition>
  <condition>Complete Remission</condition>
  <condition>Metastasis</condition>
  <arm_group>
    <arm_group_label>Biopsy cCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, we add multi-points and full-thickness Biopsy to further improve the accuracy of cCR after neoadjuvant therapy for rectal cancer.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional cCR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Based on digital examination, serum CEA level, rectal MRI, endoscopy presentation, to study accuracy of cCR after neoadjuvant therapy for rectal cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multi-points and full-thickness Biopsy</intervention_name>
    <description>Four points around the tumor site and center of the tumor site full-thickness Biopsy</description>
    <arm_group_label>Biopsy cCR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>traditional cCR</intervention_name>
    <description>diginal examination, endoscopy test, rectal MRI, and serum CEA level</description>
    <arm_group_label>Conventional cCR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult male and female, between 18 and 80 years old;&#xD;
&#xD;
          -  Colonoscopy biopsy pathology confirmed colorectal adenocarcinoma;&#xD;
&#xD;
          -  The distance from the lower margin of the tumor to the anal margin ≤12 cm (endoscope)&#xD;
             or to the anorectal ring ≤8 cm;&#xD;
&#xD;
          -  The hematopoietic functions of heart, lung, liver, kidney and bone marrow meet the&#xD;
             requirements of surgery and anesthesia;&#xD;
&#xD;
          -  Initial local MRI stage was T2 or T3A or T3B, N0-2, negative for extramural vascular&#xD;
             invasion (EMVI), circumferential ential resection margin (CRM), and no peripheral&#xD;
             iliac, common iliac, obturator, or abdominal aortic lymph node metastasis;&#xD;
&#xD;
          -  CCR patients evaluated after neoadjuvant therapy (no mass or ulcer found on digital&#xD;
             rectal examination;Endoscopic examination showed no other changes except flat scar,&#xD;
             telangiectasia or pallor of mucosa.MRI or rectal ultrasound showed no residual tumor&#xD;
             in the primary site and lymphatic drainage area.Serum carcinoembryonic antigen (CEA)&#xD;
             was normal.&#xD;
&#xD;
          -  Signing informed consent for surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous history of malignant colorectal tumor;&#xD;
&#xD;
          -  Patients complicated with intestinal obstruction, intestinal perforation, intestinal&#xD;
             bleeding and other patients requiring emergency surgery;&#xD;
&#xD;
          -  Unresectable lymph node metastasis;&#xD;
&#xD;
          -  Recently diagnosed with other malignant tumors;&#xD;
&#xD;
          -  Patients who had participated in or were participating in other clinical trials within&#xD;
             4 weeks prior to enrollment;&#xD;
&#xD;
          -  ASA rating ≥IV and/or ECOG physical status score ≥2 points;&#xD;
&#xD;
          -  Patients with severe liver and kidney function, cardiopulmonary function, coagulation&#xD;
             dysfunction or combined with serious basic diseases cannot tolerate surgery;&#xD;
&#xD;
          -  a history of serious mental illness;&#xD;
&#xD;
             - pregnant or lactating women;&#xD;
&#xD;
          -  Those with uncontrolled infection;&#xD;
&#xD;
          -  Patients with other clinical or laboratory conditions considered by the investigator&#xD;
             should not participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenjun Wang</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Chao Yang Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jiagang Han</last_name>
    <phone>86-10-85231604</phone>
    <email>hanjiagang@ccmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Zhiwei Zhai</last_name>
    <phone>86-10-85231604</phone>
    <email>913916215@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Chaoyang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiagang Han</last_name>
      <phone>86-0-13522867841</phone>
      <email>hjg211@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhenjun Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 4, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Chao Yang Hospital</investigator_affiliation>
    <investigator_full_name>Zhen Jun Wang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>rectal cancer</keyword>
  <keyword>neoadjuvant therapy</keyword>
  <keyword>clinical complete remission</keyword>
  <keyword>full-thickness biopsy</keyword>
  <keyword>watch-and wait</keyword>
  <keyword>regrowth</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

